Torrent Pharmaceuticals faced a ₹413.4 million (₹41.34 crore) penalty from the tax department for alleged discrepancies, likely under income tax or GST provisions. The company plans to challenge the order via appeal, asserting no material financial impact amid strong Q2 performance.
Penalty Details
Torrent Pharmaceuticals Ltd, a leading player in cardiovascular and CNS therapeutics, received a substantial penalty of ₹413.4 million imposed by the tax department. This follows similar recent notices, including a ₹2.32 crore income tax penalty under Section 271(1)(c) for tax adjustments and smaller GST fines, highlighting ongoing regulatory scrutiny in pharma taxation.
Company Response
Torrent maintains the penalty lacks merit and will pursue appeals at higher forums, consistent with its handling of prior demands like NPPA overcharging notices totaling ₹6-60 lakh. With Q2 FY26 net profit at ₹453 crore on ₹2,889 crore revenue, the firm views it as immaterial to operations or finances.
Key Highlights:
Penalty Amount: ₹413.4 million (₹41.34 crore) from tax authorities.
Basis: Alleged tax adjustments or excess claims; akin to recent ₹2.32 Cr income tax order.
Action Plan: Immediate appeal expected; no material impact anticipated.
Financial Context: Robust Q2 growth (17% profit rise); shares rallied post prior disclosures.
Sources: Business Standard, Medical Dialogues, Moneycontrol, Economic Times